NEW YORK – Baylor Genetics and Baylor College of Medicine said Monday that they launched a joint clinical diagnostic lab venture called the Medical Genetics Multi-Omics Laboratory (MGML).
The MGML recently launched its first test, Whole Transcriptomic RNA Sequencing (WT RNAseq), which is used to identify candidate disease-causing genes from blood and skin cells, which might have been missed during whole-genome and/or whole-exome sequencing.
The test is currently offered to the Undiagnosed Diseases Network (UDN) through Baylor Genetics, which has provided a range of sequencing, interpretation, validation, and reporting services for the UDN's sequencing core since 2014.
MGML aims to expand its offerings for both commercial and clinical settings going forward.
"This agreement, and the MGML lab, bring to life our vision of innovation, allowing us to codevelop new tests, evaluate [them] in terms of clinical utility, and offer [them] commercially in either a research or clinical setting," Brendan Lee, professor of molecular and human genetics at Baylor College of Medicine, said in a statement.